Published DateClear

Start Date

End Date

Category

• Products3

Organizations

• Bausch + Lomb77
• Eyes On Eyecare58
• Alcon, Inc.52
• American Optometric Association42
• Harrow35
• Glaukos31
• Topcon Healthcare26
• Regeneron25
• Coopervision23
• Aldeyra Therapeutics21

Tags

• AMD3
• DME3
• Diabetic Retinopathy3
• Eylea2
• Biosimilar2
• Injections2
• Products2
• Retina2
• Retinal Vein Occlusion (rvo)2
• Wet Amd2

• Organizations: Biocon Biologics✕

Clear all

Products

Biocon launches Eylea biosimilar to US market

With commercial rights acquired from Santen, YESAFILI (aflibercept-jbvf) is indicated for the treatment of AMD, DME, DR, and macular edema following RVO.

Products

Settlement paves way for US commercialization of Eylea biosimilar

Biocon Biologic’s YESAFILI (aflibercept-jbvf) now expected to launch in H2 2026 after dismissal of Regeneron’s patent infringement lawsuits.

Products

FDA approves first interchangeable aflibercept biosimilars

Generic equivalents to Eylea demonstrate a comparable quality, safety, and efficacy profile for wet AMD, DME, RVO, and DR.